Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Conditions

Colorectal Neoplasms 476Carcinoma, Non-Small-Cell Lung 233Breast Neoplasms 196Ovarian Neoplasms 171Glioblastoma 157Carcinoma, Hepatocellular 131Neoplasms 128Rectal Neoplasms 114Colonic Neoplasms 110Neoplasm Metastasis 106Brain Neoplasms 97Lung Neoplasms 96Fallopian Tube Neoplasms 85Carcinoma, Renal Cell 77Glioma 69Pancreatic Neoplasms 54Liver Neoplasms 44Melanoma 43Gliosarcoma 43Uterine Cervical Neoplasms 40Adenocarcinoma of Lung 39Stomach Neoplasms 37Recurrence 33Astrocytoma 30Carcinoma, Ovarian Epithelial 28Endometrial Neoplasms 27Triple Negative Breast Neoplasms 26Kidney Neoplasms 23Prostatic Neoplasms 22Esophageal Neoplasms 21

Interventions

Cetuximab 2Bevacizumab 2trifluridine tipiracil drug combination 1S 1 (combination) 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
mCRC × Bevacizumab × Clear all
NCT07116577 2025-08-11

Radiotherapy Combined QL1706, TAS-102 and Bevacizumab in mCRC

Jinan Central Hospital

Phase 2 Not yet recruiting
37 enrolled

mCRC

NCT03567629 2018-06-26

Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer

Peking University

Phase 2 Unknown
130 enrolled

mCRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡